

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior version, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended) A method of screening for deviation from normality indicative of a premalignant or neoplastic disease state in the squamous cells of a cervical smear sample containing cells of the cervix, the method comprising contacting said sample with a panel of two or more monoclonal antibodies, wherein said panel binds to surface antigens on normal cells of the cervix in a pattern which represents normality, said panel including at least one monoclonal antibody specific for columnar cells and at least one monoclonal antibody specific for squamous cells, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein the percentage binding of the ~~at least one monoclonal antibody or antibodies~~ specific for squamous cells binding to premalignant or neoplastic abnormal squamous cells is increased or decreased with respect to the binding of the said monoclonal antibody or antibodies to normal squamous cells in the cervical smear sample.
2. (previously presented) A method according to Claim 1 wherein the monoclonal antibodies comprise one or more polypeptides each comprising an antigen binding domain.

3. (currently amended) A method of screening for deviation from normality indicative of ~~determining~~ a premalignant or neoplastic disease state in the squamous cells of a cervical smear sample containing cells of the cervix, the method comprising contacting a panel of two or more monoclonal antibodies with said sample, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein the percentage ~~binding of the monoclonal antibody or antibodies specific for squamous cells two or more monoclonal antibodies binding to premalignant or neoplastic~~ abnormal squamous cells is increased or decreased with respect to the binding of the said monoclonal antibody or antibodies to normal squamous cells in the cervical smear sample, and wherein the panel includes one or more monoclonal antibodies comprising one or more polypeptides each comprising an antigen binding domain obtained from a hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.
4. (previously presented) A method according to Claim 1 wherein one or more of the monoclonal antibodies comprise a polypeptide able to bind to an antigen which can be bound by one or more antibodies obtained from a hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.

5. (previously presented) A hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.
6. (cancelled)
7. (previously presented) A specific monoclonal antibody comprising an immunoglobulin antigen binding domain obtained from a hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.
8. (cancelled)
9. (cancelled)
10. (previously presented) The method as claimed in Claim 1 wherein said panel of monoclonal antibodies comprises a monoclonal antibody having an antigen binding domain obtainable from a hybridoma deposited at the European Collection of Animal Cell Cultures (ECACC) under the accession number ECACC 95020716.
11. (cancelled)
12. (previously presented) The method as claimed in Claim 3 wherein said panel includes a monoclonal antibody comprising an antigen binding domain obtained from the hybridoma deposited under Accession Number ECACC 95020716.